The first human case of a new strain of avian flu was diagnosed in China in late May. Chinese health authorities say there is a low risk of contagion. After China notoriously underreported COVID-19 mortality, can this new assurance be trusted?

With Lyme disease season emerging and the Covid-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two (as well as the flu) so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.

Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator.

A recent study published in Science Translational Medicine shows that a new flu vaccine appears to protect monkeys against influenza strains that are likely to cause a global pandemic, giving researchers hope that this vaccine could hold the key to providing a future universal flu vaccine for humans.

The U.S. health regulator granted emergency use authorization for Abbott Laboratories’ molecular test to detect and distinguish the coronavirus and two types of flu viruses with a single test.

Vir Biotechnology and GlaxoSmithKline expanded a collaboration to develop strategies against COVID-19 to include work into new treatments for influenza and other respiratory viruses.

A molecular test from Becton Dickinson that detects viruses that cause Covid-19 as well as influenza and produces result in 2-3 hours was given emergency use authorization by the U.S. health regulator.

Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else is going on with these companies.

Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.